REGENXBIO
RGNX
Performance
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company focused on gene therapy. The company develops therapies using its NAV® Technology Platform to deliver one-time treatments for retinal, metabolic, and neurodegenerative diseases, aiming to improve lives for patients. Based in the United States, it emphasizes advancing novel AAV-based gene therapies through steady clinical programs and partnerships.
Recent News
Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA
Labiotech’s 15 Biopharma Companies to Watch in 2026
FDA’s Accelerated Approval Messaging Collides with CRL Reality
At Least Nine PDUFAs on FDA February Docket
Biopharma Catalysts in Q2 2026 Signal High-Profile Approval Decisions and Rising Competition
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
REGENXBIO Hit with Securities Fraud Class Action; Lead Plaintiff Deadline Set for April 14
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
JPM Day 3: Rare Disease in the Spotlight
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
STAT+: FDA Rejects Regenxbio’s Rare-Disease Gene Therapy
Recent Deals
No recent deals for this company.
